- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01228422
Pharmacokinetics and Pharmacodynamics of Interferon Alpha 2A (interferon)
Study of Pharmacokinetics and Pharmacodynamics of Alpha Interferon-2A of Blausiegel Trade and Industry the Compared the Product Roferon A, of Laboratory of Roche
Study Overview
Detailed Description
The Interferons (IFNs) are a group of cytokines produced by vertebrates in response to various stimuli, including the presence of foreign nucleic acids in the body, bacteria, tumor cells and viral antigens. These proteins have significant shares immunomodulatory, antiproliferative and antiviral drugs, the first line of defense of the body. Once produced, the IFNs block viral replication, maximize the lytic activity of natural killer cells, increase the expression of MHC class I in cells infected by viruses and induce the development of Th1 cells The production of interferon alpha-2A is now held by biotechnology with the establishment of a chain of DNA producer of interferon alpha-2a in the chain of original DNA of a bacterium, allowing the bacteria produce this drug on an industrial scale. In the process of synthesis, the 165 amino acids that are part of this molecule can change in your order with no reduction in activity or changes in the properties.
Due to this fact, the biological and medicinal considered, especially those in manufacturing by genetic engineering, need to prove their clinical activity so that they can be marketed. In the case of interferon, the consequences of the use of a product without activity compared to treat patients with Hepatitis C can lead to serious health complications from them. It is therefore necessary to prove its clinical activity and pharmacokinetics before its clinical efficacy. The sponsor of this study aims to end the renewal of registration of interferon alpha-2A with the Ministry of Health So this study to evaluate the Pharmacokinetics and Pharmacodynamics of interferon alpha-2a may allow in the future this medicine can be used by a year in patients with hepatitis C, without risk to their health, besides those already known and inherent in the treatment of any interferon.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Sao Paulo
-
Valinhos, Sao Paulo, Brazil, 13270000
- LAL Clínica Pesquisa e Desenvolvimento Ltda
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Accepting the End of Free and Informed Consent;
- Research subjects were male, aged 18 to 55 years;
- Research subjects with body mass index ≥ 19 and ≤ 30;
- Be considered healthy, from the analysis of medical history, medical examination and laboratory tests within the normal range.
Exclusion Criteria:
- Results of laboratory tests outside the values considered acceptable in accordance with the criteria of medical evaluator;
- Having participated in any experimental study or have ingested any experimental drug in the last three months before the start of the study;
- Have made regular use of medication in the past 4 weeks preceding the start of the study or have made use of any medication a week before the start of the study;
- Have been hospitalized for any reason, up to 8 weeks before the start of the study;
- Present history of abuse of alcohol, drugs or medications, or have ingested alcohol within 48 hours prior to the period of stay;
- Have a history of liver disease, renal, pulmonary, gastrointestinal, hematological or psychiatric;
- Present pressure changes of any cause that requires pharmacological treatment; present history of myocardial infarction, angina and / or heart failure;
- Have donated or lost 450 ml of blood or more in the three months preceding the study
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1
test interferon - blausiegel
|
3MUI
|
2
reference interferon - Roferon A (Roche)
|
3MUI
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate in parallel pharmacodynamic parameters and pharmacokinetics.
Time Frame: 96 hours.
|
Pharmacokinetic parameters of the drug will be held 17 blood samples over a period of 96 hours.
The parameters Cmax, Tmax, area under the curve (AUC), among others, will be quantified in each individual.
The pharmacodynamics will be studied from the alteration of endogenous biomarkers sensitive to stimulation by interferon.
|
96 hours.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of clinical safety through a comparison of clinical and laboratory parameters pre-and post-study and the incidence of adverse events
Time Frame: 96 hours.
|
The pharmacokinetic parameters of the drug will be held 17 blood samples over a period of 96 hours.
The parameters Cmax, Tmax, area under the curve (AUC), among others, will be quantified in each individual.
The pharmacodynamics will be studied from the alteration of endogenous biomarkers sensitive to stimulation by interferon.
|
96 hours.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alexandre Frederico, Doctor, Azidus Brasil
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Will be studied 24 subjects divided Research and 2 parallel groups
- The treatment is a dose of 3MUI of alpha interferon 2nd
- There will be collection of blood at times: 0, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 hours.
- The volunteers will be hospitalized 24 hours.
- Will be measured labels the AUC, Tmax, Cmax, neopterin and beta2-microglobulin
Additional Relevant MeSH Terms
Other Study ID Numbers
- INT2ABLA0908
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Interferon alpha 2a
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
University Hospital TuebingenDermatologic Cooperative Oncology GroupCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedBreast Cancer | Metastatic CancerUnited States
-
Huashan HospitalUnknown
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
The Wistar InstituteNational Institute of Allergy and Infectious Diseases (NIAID); Hoffmann-La... and other collaboratorsCompleted
-
BioGeneric PharmaXiamen Amoytop Biotech Co., Ltd.UnknownHepatitis C | Self EfficacyEgypt
-
Vir Biotechnology, Inc.Alnylam PharmaceuticalsActive, not recruitingChronic Hepatitis BAustralia, Hong Kong, Korea, Republic of, Malaysia, New Zealand, Thailand
-
M.D. Anderson Cancer CenterCompleted